Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> CFTR>>NVS1.1

NVS1.1

Catalog No.GC79075 Copy One-Click Copy Product Info

NVS1.1 is an orally active, blood-brain barrier-penetrant eRF1 degrader.

Products are for research use only. Not for human use. We do not sell to patients.

NVS1.1 Chemical Structure

Size Price Stock Qty
1mg
$439.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.



Description of NVS1.1

NVS1.1 is an orally active, blood-brain barrier-penetrant eRF1 degrader. NVS1.1 induces ubiquitination of eRF1 at Lys279, mediates proteasomal degradation via the E3 ubiquitin ligases RNF14 and RNF25 as well as the translational stress sensor GCN1, traps eRF1 at the ribosomal A-site, inhibits translation termination and triggers ribosome collision. As a readthrough enhancer, NVS1.1 enables near-cognate tRNA incorporation at premature termination codons by reducing intracellular eRF1 levels. NVS1.1 activates ribosome-associated quality control pathways via ribosome collision, including ubiquitination of small subunit ribosomal proteins. NVS1.1 restores functional full-length CFTR and IDUA proteins and reduces glycosaminoglycan accumulation in relevant models. NVS1.1 can be used in the research of cystic fibrosis and Hurler syndrome (mucopolysaccharidosis type I, MPS I) [1].

In Vivo, NVS1.1 (20-40 mg/kg; p.o.; daily; 14 days) restores ~1% wild-type IDUA activity and reduces brain GAG levels by up to 57% in a rat model of Hurler syndrome[1].

In Vitro, NVS1.1 (1-10 μM; 48 h) dose-dependently restores functional IDUA enzymatic activity in HEKR4 cells expressing the IDUAQ70X or IDUAW402X nonsense mutations[1]. NVS1.1 (0.1-10 μM for 7 days, 0-0.6 μM for 7 weeks) dose-dependently restores IDUA activity, reduces GAG accumulation, normalizes GUSB activity, and is accompanied by eRF1 depletion in primary fibroblasts from homozygous IDUAW402X Hurler syndrome patients[1]. NVS1.1 (0.00-5.00 μM; 8-24 h) increases the level of IDUA-W402X mRNA in primary fibroblasts from Hurler syndrome patients[1]. NVS1.1 (2.5 μM; 6 h) induces proteasomal degradation of eRF1 in HEKR4 PTC reporter cells, and this degradation process does not require neddylation modification of Cullin-RING ligases[1]. NVS1.1 (25 μM; 30 min) induces ubiquitination modification of eRF1 in HeLa and HEKR4 PTC cells[1]. The process by which NVS1.1 (0.00-2.5 μM; 6 h) induces eRF1 degradation in HEKR4 PTC reporter cells requires the catalytically active E3 ubiquitin ligases RNF14 and RNF25[1]. The nonsense codon readthrough-inducing effect of NVS1.1 (0.1-10 μM; 24 h) in HEKR4 PTC reporter cells depends on catalytically active RNF14 and RNF25[1]. NVS1.1 (2.5 μM; 6 h) requires GCN1 to induce the degradation of eRF1 in HEKR4 cells[1].

References:
[1]. Gurzeler LA, et al. Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control. Cell reports. 2023 Sep 26;42(9):113056.

Chemical Properties of NVS1.1

Cas No. SDF
Formula C17H16ClN3O2S M.Wt 361.85
Solubility Storage Store at -20°C
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of NVS1.1

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.7636 mL 13.8179 mL 27.6358 mL
5 mM 552.7 μL 2.7636 mL 5.5272 mL
10 mM 276.4 μL 1.3818 mL 2.7636 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of NVS1.1

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % saline
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Reviews

Review for NVS1.1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%